Therefore, in screening algorithms for patients with CRC, analysis of BRAF is a cost-effective method to screen for patients who should undergo further genetic testing for LS rather than gene sequencing in all those with absence of MLH1 and PMS2 [50, 51]. This evidence concerns the gene MLH1 and colorectal carcinoma.